Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

• Status: Terminated
• Trial end date: 2017-07-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sherif S. Farag
• Treatments: Antilymphocyte Serum; Fludarabine; Fludarabine phosphate; Thiotepa; Thymoglobulin

Criteria

Inclusion Criteria:

• Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria

• CR 1 with poor risk features

• CR 2, or higher order CR

• Acute lymphoblastic leukemia (ALL) with one of the following criteria

• CR 1 with poor risk features

• CR 2, or higher order CR

• Myelodysplasia, RAEB I

• Donor has been identified

• Age ≤ 65 years.

• Performance Status 0-1.

Exclusion Criteria:

• Patients relapsing <6 months after autologous SCT are not eligible.

• Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.

• Non-pregnant and non-nursing